ACO REACH: An Innovative Step Towards Health Equity

By Staff Writer

October 29, 2023

Understanding ACO REACH and its Impact

Launched in January 2023, Accountable Care Organisation Realising Equity, Access, and Community Health (ACO REACH), initiated by the Centers for Medicare and Medicaid Services (CMS), has taken a strategic leap towards equity in healthcare. The model is designed to promote health equity through payment model design, data collection on social drivers of health, and financial incentives linked to equity.

A key feature of ACO REACH is the Health Equity Benchmark Adjustment (HEBA). This adjustment allows for increases or decreases in participants’ financial benchmarks based on the beneficiaries they serve. The goal? To remove the disincentives to serve marginalised populations by acknowledging the extra costs of caring for these groups.

Changes to HEBA Calculations in 2024

As we move into 2024, Medicare is taking on board stakeholder feedback and revising its approach to HEBA calculations. This change is significant, as it marks one of the first attempts to alter financial targets based on non-medical factors.

The way HEBA scores are calculated will also undergo changes. Currently, the HEBA is based on measures of individual beneficiary income and area-level social need. However, from next year, CMS will incorporate beneficiaries’ state ADI, a measure that ranks the social need in a beneficiary’s neighbourhood against the need in other neighbourhoods across a given state.

The implications of these changes are substantial. They represent a pragmatic way to improve policymakers’ ability to identify individuals with low-income and high health-related need.

In conclusion, ACO REACH is one of the first models to reflect a national call to action for health care stakeholders to go beyond traditional approaches to value-based payment and address equity. 

Reference url

Recent Posts

lenacapavir HIV PrEP access
    

Global Health Partnerships Unite to Expand Access to Lenacapavir for HIV Prevention

💉 How can we ensure equitable access to HIV prevention methods like lenacapavir?

A recent initiative from the Global Fund, supported by key global health organizations, aims to provide affordable access to this new HIV pre-exposure prophylaxis medication.

With a goal to reach 2 million individuals over three years, this coordinated effort seeks to drastically cut HIV infections and align with our commitment to ending AIDS by 2030.

Explore the details of this impactful collaboration and how it could transform HIV prevention.

#SyenzaNews #globalhealth #HealthcareInnovation #MarketAccess

antimicrobial resistance africa
     

Africa’s Health Crisis: Antimicrobial Resistance and Mpox Outbreak

🌍 Are we prepared to tackle the hidden pandemic of antimicrobial resistance (AMR) in Africa?

With AMR rapidly becoming a dominant health crisis, it’s critical to understand its impact on our healthcare systems and most vulnerable populations.

The Africa CDC highlights the urgent need for substantial investment and coordinated responses to combat this escalating threat, alongside the ongoing Mpox outbreak.

Discover the pressing challenges and potential solutions in our latest article.

#SyenzaNews #GlobalHealth #HealthcareInnovation #AntimicrobialResistance #PublicHealth

BioSapien cancer drug delivery
    

BioSapien Innovative Cancer Drug Delivery Solutions

🌟 How is innovation in drug delivery shaping the future of cancer treatment? 🌟

Discover how UAE-based BioSapien is transforming the healthcare landscape with the MediChip™ platform, securing $5.5 million in pre-Series A funding to enhance cancer care.

This innovative solution promises to minimise side effects and improve treatment outcomes for patients, fully embracing the potential of biotechnology in the fight against cancer.

Read more about BioSapien’s journey and its impact on global health!

#SyenzaNews #biotechnology #oncology #innovation #HealthTech

When you partner with Syenza, it’s like a Nuclear Fusion.

Our expertise are combined with yours, and we contribute clinical expertise and advanced degrees in health policy, health economics, systems analysis, public finance, business, and project management. You’ll also feel our high-impact global and local perspectives with cultural intelligence.

SPEAK WITH US

CORRESPONDENCE ADDRESS

1950 W. Corporate Way, Suite 95478
Anaheim, CA 92801, USA

© 2024 Syenza™. All rights reserved.